Table 3.
Reproductive hormones, ferroptosis, apoptotic and oxido-inflammatory status.
| Parameters | I Control (n = 15) |
II PCO (n = 15) |
III PCO treated with AgNPs (n = 15) |
IV PCO treated with Zileuton (n = 15) |
V PCO treated with AgNPs + Zileuton (n = 15) |
P-value |
|---|---|---|---|---|---|---|
| Estradiol (pg/ml) | 14.5±.85 | 5 ± 1.61 a, c, d, e | 12 ± 1.05 a, b, d, e | 9.4 ± 1.2 a, b, c, e | 13.8 ± 1.7 b, c, d | P < 0.05 |
| Testosterone (ng/ml) | 0.31 ± 0.08 | 2.7 ± 0.25 a, c, d, e | 0.62 ± 0.07 a, b, d, e | 0.82 ± 0.06 a, b, c, e | 0.37 ± 0.03 b, c, d | P < 0.05 |
| LH (mIU/mL) | 0.87 ± 0.07 | 7.6 ± 0.6 a, c, d, e | 3.6 ± 0.6 a, b, e | 4.8 ± 1.4 a, b, e | 1.1 ± 0.2 b, c, d | P < 0.05 |
| FSH (mIU/mL) | 4.6 ± 0.68 | 1.5 ± 0.4 a, c, d, e | 2.2 ± 0.1a, b, e | 2.03 ± 0.3 a, b, e | 3.8 ± 0.45 b, c, d | P < 0.05 |
| LH/FSH ratio | 0.18 ± 0.01 | 5.3 ± 0.2 a, c, d, e | 1.5 ± 0.1 a, b, d, e | 1.2 ± 0.07 a, b, c, e | 0.42 ± 0.16 b, c, d, e | P < 0.05 |
| Fe + 2(nmol/mg tissue) | 0.2 ± 0.01 | 0.46 ± 0.03 a, d, e | 0.49 ± 0.04 a, d, e | 0.21 ± 0.03 b, c | 0.23 ± 0.06 b, c | P < 0.05 |
| HO-1 (nmol bilirubin/mg tissue protein/hour) | 1.6 ± 0.2 | 0.5 ± 0.1 a, d, e | 0.65 ± 0.22 a, d, e | 1.46 ± 0.4 b, c | 1.5 ± 0.3 b, c | P < 0.05 |
| TNF- α (pg/ml) | 49.8 ± 1.1 | 172.8 ± 11 a, c, d, e | 56.5 ± 5.5 b | 51.6 ± 3.08 b | 50.4 ± 6.5 b | P < 0.05 |
| NFκ-B (ng/ml) | 3.5 ± 0.4 | 13.2 ± 0.8 a, b, d, e | 3.8 ± 0.7 b | 3.7 ± 0.7 b | 3.3 ± 0.5 b | P < 0.05 |
| IL-6 (pglml) | 4.33 ± 0.45 | 11.3 ± 1.1 a, c, d, e | 4.6 ± 0.43 b | 4.4 ± 0.4 b | 4 ± 0.1 b | P < 0.05 |
| MDA (nmol/mg protein) | 2.6 ± 0.36 | 9.1 ± 0.3 a, c, d, e | 4.1 ± 0.32 a, b, e | 4.3 ± 0.61 a, b, e | 2.5 ± 0.35 b, c, d | P < 0.05 |
| Caspase 3 (ng/ml) | 2.4 ± 0.26 | 8.6 ± 1.6 a, c, d, e | 2.6 ± 0.7 b | 3.06 ± 1 b | 2.3 ± 0.37 b | P < 0.05 |
| GPX (IU/g tissue) | 26.06 ± 0.25 | 12.6 ± 1.3 a, c, d, e | 24.9 ± 1.9 b | 25.6 ± 0.4 b | 25.2 ± 2.1 b | P < 0.05 |
Note: Mean ± SD is used to represent data. HO-1; heme oxygenase 1, FSH; follicular stimulating hormone, LH; luteinizing hormone. TNF- α; tumour necrosis factor alpha, NFκ-B; nuclear factor kappa beta, IL-6; interleukin 6, MDA; malonaldehyde, GPX; glutathione peroxidase. ap < 0.05 vs. control group I, bp < 0.05 vs. PCO group II, cp < 0.05 vs. AgNPs-treated group III, dp < 0.05 vs. Zileuton-treated group IV, ep < 0.05 vs. AgNPs + Zileuton co-treated group V.